Remission of lymphoma and rheumatoid arthritis following ant…
Emerging
6
Citations5
Refs2024
Year
Search Works
Work Details
- DOI 10.1093/rheumatology/keae714
- PMID https://pubmed.ncbi.nlm.nih.gov/39718785
- OpenAlex ID W4405757350
- Type Article
- Language EN
- Published 24 Dec 2024
- Volume 64 (5)
- Pages 3183–3185
- Source Lara D. Veeken
- Publisher Oxford University Press
- FWCI 1.03
- Countries 1
- Institutions 1
- Added 25 Dec 2024
- Updated 27 Oct 2026
External Links
MENU
0
Remission of lymphoma and rheumatoid arthritis following anti-CD19 chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma
Article 2024 EN
Remission of lymphoma and rheumatoid arthritis with CD19 CAR T-cell therapy Dear Editor, Chimeric antigen receptor (CAR) T-cell therapy is a genetically modified autologous T-cell immunotherapy that has demonstrated effectiveness in the treatment of various hematologic malignancies, with response rates of 40–54% and 69–74% in patients with relapsed and/or recurrent aggressive B-cell lymphomas and…
6
Citations
5
References
4
Authors
1.03
FWCI
Citations by Year
Last 2 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
4 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Aliya Masihuddin Corresponding | — | — |
| 2 | Jason E. Liebowitz | Columbia University Irving Med… (US) | |
| 3 | Ran Reshef | Columbia University Irving Med… (US) | |
| 4 | Joan M. Bathon | Columbia University Irving Med… (US) |
Related Works
10Data: OpenAlex